Yazar "Goker, E." seçeneğine göre listele
Listeleniyor 1 - 20 / 20
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial(Oxford Univ Press, 2018) Goss, G. D.; Cobo, M.; Lu, S.; Syrigos, K.; Lee, K. H.; Goker, E.; Georgoulias, V.; Li, W.; Isla, D.; Morabito, A.; Min, Y. J.; Ardizzoni, A.; Cseh, A.; Bender, S.; Felip, E.Öğe Alveolar rhabdomyosarcoma originating from the uterine cervix(I R O G Canada, Inc, 2011) Cakar, B.; Muslu, U.; Karaca, B.; Junushova, B.; Uslu, R.; Goker, E.Cervical alveolar rhabdomyosarcoma is a rare condition associated with poor prognosis. An 18-year-old patient presented with vaginal bleeding and a protruding mass from the vagina. Biopsy of the mass revealed alveoler rhabdomyosarcoma (ARMS), and radiological evaluation demonstrated that it originated from the uterine cervix. First, Wertheim's operation was carried out followed by four cycles of vincristine, actinomycine-D, ifosfamide (VAI) chemotherapy. However, the disease relapsed within three months, and the patient died of disease progression. Despite combination treatment, we could not achieve a desirable survival advantage in ARMS. Future studies may unveil the genomic profile of this rare condition, leading to invention of targeted therapies, which is the emerging trend in the treatment of sarcomas.Öğe Arsenic trioxide exposure to ovarian carcinoma cells leads to decreased level of topoisomerase II and cytotoxicity(Blackwell Publishing, 2006) Askar, N.; Cirpan, T.; Toprak, E.; Karabulut, B.; Selvi, N.; Terek, M. C.; Uslu, R.; Sanli, U. A.; Goker, E.The objective of this study was to investigate the effect of arsenic trioxide (As2O3) on topoisomerase II levels using western blotting method on MDAH 2774 ovarian carcinoma cell culture. Experimental designs were established to determine the cytotoxic effects of As2O3 on MDAH 2774 cells and the IC50 (fatal dose for the 50% of cells) value. Cytotoxicity experiments were carried out using various concentrations of As2O3. The 2,3-bis[2-methyloxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide (XTT) and trypan blue dye-exclusion tests were used to evaluate cytotoxicity. Topoisomerase II expressions were investigated using western blotting method with various concentrations of As2O3. Densitometric analysis of topoisomerase 2 bands was carried out using Quantity One 1-D analysis software (Bio-Rad USA, Life Science Research, Hercules, CA). IC50 value of As2O3 was found to be 5 x 10(-6) M for MDAH 2774 cells. When the bands were evaluated, it was observed that there was a decrease in topoisomerase II levels in MDAH 2774 cells with increasing concentrations of As2O3. It was also observed by the densitometric analysis that topoisomerase II expression ratios of MDAH 2774 cells were decreased by approximately 50% at this concentration. Topoisomerase II levels were significantly decreased with the increasing concentrations of As2O3. Inhibition of topoisomerase II enzyme was one of the antiproliferative influence mechanisms of As2O3.Öğe The changing pattern of risk factors and disease characteristics of breast cancer in Turkey: A cross-sectional study of a Turkish oncology group (BREASTTURK)(Amer Soc Clinical Oncology, 2011) Akbulut, H.; Altundag, M. K.; Saip, P.; Coskun, H. S.; Camci, C.; Ozkan, M.; Paydas, S.; Zengin, N.; Alco, G.; Aliustaoglu, M.; Basaran, G.; Yamac, D.; Yucel, I.; Goker, E.; Yaman, E.; Isikdogan, A.; Ozisik, Y. Y.; Topuz, E.; Ozdogan, M.; Icli, F.Öğe Concurrent radiochemotherapy with carboplatin and paclitaxel followed by consolidation chemotherapy in patients with inoperable stage III non-small cell lung cancer (NSCLC)(Elsevier Ireland Ltd, 2006) Serdar, Ozkok; Dubova, S.; Guersel, C.; Yalman, D.; T Goeksel; Goker, E.Öğe Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung(Oxford Univ Press, 2016) Goss, G.; Lee, K. H.; Felip, E.; Cobo, M.; Syrigos, K.; Goker, E.; Georgioulias, V.; Guclu, S. Z.; Isla, D.; Min, Y. J.; Morabito, A.; Dupuis, N.; Chand, V. K.; Solca, F.; Kraemer, N.; Gibson, N.; Ehrnrooth, E.; Soria, J. C.Öğe Gemcitabine and the monoclonal antibody nimotuzumab versus gemcitabine and placebo for the treatment of chemotherapy-naive patients (pts) with advanced pancreatic cancer (PC): A multicentre, randomized phase IIb/IIIa study(Karger, 2014) Strumberg, D.; Schultheis, B.; Ebert, M. P.; Siveke, J.; Kerkhoff, A.; Berdel, W.; Hofheinz, R.; Behringer, D. M.; Schmidt, W. E.; Goker, E.; De Dosso, S.; Kneba, M.; Yalcin, S.; Overkamp, F.; Schlegel, F.; Dommach, M.; Rohrberg, R.; Steinmetz, T.; Reuter, D.; Bach, F.Öğe Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study(Oxford Univ Press, 2017) Schultheis, B.; Reuter, D.; Ebert, M. P.; Siveke, J.; Kerkhoff, A.; Berdel, W. E.; Hofheinz, R.; Behringer, D. M.; Schmidt, W. E.; Goker, E.; De Dosso, S.; Kneba, M.; Yalcin, S.; Overkamp, F.; Schlegel, F.; Dommach, M.; Rohrberg, R.; Steinmetz, T.; Bulitta, M.; Strumberg, D.Background: This randomized study was designed to investigate the superiority of gemcitabine (gem) plus nimotuzumab (nimo), an anti-epidermal growth factor receptor monoclonal antibody, compared with gem plus placebo as first-line therapy in patients with advanced pancreatic cancer. Patients and methods: Patients with previously untreated, unresectable, locally advanced or metastatic pancreatic cancer were randomly assigned to receive gem: 1000 mg/m(2), 30-min i.v. once weekly (d1, 8, 15; q29) and nimo: fixed dose of 400 mg once weekly as a 30-min infusion, or gem plus placebo, until progression or unacceptable toxicity. The primary end point was overall survival (OS), secondary end points included time to progression, overall response rate, safety and quality of life. Results: A total of 192 patients were randomized, with 186 of them being assessable for efficacy and safety (average age 63.6 years). One-year OS/progression-free survival (PFS) was 34%/22% for gem plus nimo compared with 19%/10% for gem plus placebo (HR = 0.69; P = 0.03/HR = 0.68; P = 0.02). Median OS/PFS was 8.6/5.1 months for gem plus nimo versus 6.0/3.4 mo in the gem plus placebo group (HR = 0.69; P = 0.0341/HR = 0.68; P = 0.0163), with very few grade 3/4 toxicities. KRAS wildtype patients experienced a significantly better OS than those with KRAS mutations (11.6 versus 5.6 months, P = 0.03). Conclusion: This randomized study showed that nimo in combination with gem is safe and well tolerated. The 1-year OS and PFS rates for the entire population were significantly improved. Especially, those patients with KRAS wildtype seem to benefit. The study was registered as protocol ID OSAG101-PCS07, NCT00561990 and EudraCT 2007-000338-38.Öğe The impact of 21-gene recurrence score (RS) scores on treatment decisions: Retrospective evaluation in Turkish early-stage breast cancer (BC) patients(Amer Soc Clinical Oncology, 2011) Basaran, G.; Saglam, S.; Tansan, S.; Demirel, M.; Gokmen, E.; Aktan, S.; Goker, E.; Kaban, K. K.; Saip, P.; Demir, G.; Bavbek, S. E.; Mandel, N. M.; Tecimer, C.; Turhal, N. S.; Garipoglu, M.Öğe Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung(Elsevier Science Inc, 2017) Goss, G.; Felip, E.; Cobo, M.; Lu, S.; Syrigos, K.; Lee, K. H.; Goker, E.; Georgoulias, V.; Li, W.; Guclu, S.; Isla, D.; Min, Y. Joo; Morabito, A.; Ardizzoni, A.; Gadgeel, S.; Gibson, N.; Kraemer, N.; Solca, F.; Cseh, A.; Ehrnrooth, E.; Soria, J.Öğe Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung(Elsevier Science Inc, 2018) Goss, G.; Cobo, M.; Lu, S.; Syrigos, K.; Lee, K. H.; Goker, E.; Georgoulias, V.; Li, W.; Isla, D.; Young, J. M.; Morabito, A.; Gadgeel, S.; Gibson, N.; Kraemer, N.; Solca, F.; Cseh, A.; Felip, E.Öğe Postoperative adjuvant gemcitabine alone and concurrent with radiation after resection of locally advanced pancreatic carcinoma(Pergamon-Elsevier Science Ltd, 2005) Ozkok, S.; Dubova, S.; Yuzer, Y.; Yalman, D.; Uslu, R.; Coker, A.; Zeytunlu, M.; Goker, E.Öğe Postoperative gemcitabine alone and concurrent with radiation therapy in locally advanced pancreatic carcinoma.(Amer Soc Clinical Oncology, 2010) Demirci, S.; Ozkok, S.; Yalman, D.; Zeytunlu, M.; Nart, D.; Yuzer, Y.; Coker, A.; Uslu, R.; Goker, E.Öğe PREVALANCE AND CLINICOPATHOLOGICAL ASSESSMENT OF INFLAMMATORY BREAST CANCER PATIENTS DIAGNOSED BETWEEN 2000 AND 2008(Oxford Univ Press, 2009) Karaca, B.; Tunali, D.; Gorumlu, G.; Degirmenci, M.; Goker, E.Öğe Randomized, multicenter, phase 3 study of 1st-line irinotecan+5FU/folinic acid vs cisplatin+5FU in patients with advanced gastric cancer - quality of life analysis(Pergamon-Elsevier Science Ltd, 2005) Pozzo, C.; Zaluski, J.; Dank, M.; Barone, C.; Valvere, V.; Peschel, C.; Wenczl, M.; Goker, E.; Bugat, R.Öğe Second-line Afatinib vs Erlotinib for Advanced Lung Squamous Cell Carcinoma: Final Analysis of the Phase 3 LUX-Lung 8 Trial(Elsevier Science Inc, 2019) Goss, G. D.; Cobo, M.; Lu, S.; Syrigos, K.; Lee, K. H.; Goker, E.; Felip, E.[No abstract available]Öğe Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders(Elsevier Sci Ltd, 2017) Gadgeel, S. M.; Soria, J. C.; Felip, E.; Cobo, M.; Lu, S.; Syrigos, K.; Lee, K. H.; Goker, E.; Georgoulias, V.; Li, W.; Guclu, S.; Isla, D.; Ardizzoni, A.; Dupuis, N.; Gibson, N.; Kraemer, N.; Buehnemann, C.; Solca, F.; Ehrnrooth, E.; Goss, G.Öğe Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers(Oxford Univ Press, 2016) Lee, K. H.; Soria, J-C.; Felip, E.; Cobo, M.; Lu, S.; Syrigos, K.; Goker, E.; Georgoulias, V.; Li, W.; Guclu, S.; Isla, D.; Ardizzoni, A.; Gadgeel, S. M.; Dupuis, N.; Gibson, N. J.; Kramer, N.; Buehnemann, C.; Solca, F.; Ehrnrooth, E.; Goss, G.Öğe SURGICAL APPROACH TO NON-COLORECTAL LIVER METASTASES: EGE UNIVERSITY EXPERIENCE(Oxford Univ Press, 2010) Karaca, C.; Yildirim, H.; Ozutemiz, O.; Goker, E.; Coker, A.Öğe What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?-Results from the lung cancer economics and outcomes research (LUCEOR) study(Elsevier Ireland Ltd, 2013) Lester, J. F.; Agulnik, J.; Akerborg, O.; Chouaid, C.; De Geer, A.; Finnern, H. W.; Herder, G. J. M.; Lungershausen, J.; Mitchell, P. L. R.; Vansteenkiste, J.; Ziske, C.; Goker, E.Background: A significant proportion of advanced non-small cell lung cancer (NSCLC) patients receive supportive treatments to manage disease-related symptoms either separately or combined with systemic anti-cancer therapy (SACT). This supportive treatment is commonly referred to as best supportive care (BSC). Definition of BSC in clinical trials and its description in published comparative and real-life NSCLC studies is limited. The lack of a consensus BSC definition makes detailed evaluations of clinical trials and comparisons between clinical trials problematic. Methods: Data were collected as part of the lung cancer economics and outcomes research (LUCEOR) study. Information on treatment and treatment outcomes from deceased stage IIIb/IV NSCLC patients across ten countries was retrospectively collected from medical records. BSC was defined as the best care available as judged by the attending physicians. Results: A total of 1327 patients' data were analyzed. Of those, 774/1327 (58%), 316/631 (50%), 123/259 (47%), 25/56(45%) and 15/26(58%) were administered treatment defined as BSC with first, second, third, fourth and fifth-line SACT respectively. In total, 346/678(51%), 149/335 (45%), 86/176(49%), 11/28 (39%) and 13/25 (52%) of patients were administered treatment defined as BSC in the end-of-life setting after finishing first, second, third, fourth and fifth-line SACT respectively. BSC therapies could be grouped into 24 different categories. The most common elements did not vary substantially whether given with SACT (irrespective of treatment line), in the end-of-life setting, or between countries. The commonest categories of BSC were narcotic and non-narcotic analgesics, corticosteroids and gastrointestinal medication. Conclusion: There were no major differences in what constituted BSC. BSC included in all instances narcotic and non-narcotic analgesics, corticosteroids and gastrointestinal medication. To our knowledge this is the first study attempting to describe BSC in routine clinical practice. This study's results could help define a practical, up to date, evidence-based definition of BSC. (C) 2013 Elsevier Ireland Ltd. All rights reserved.